Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial

27 August 2021 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Kazuma Oyama

Tohoku University, Sendai (Japan)

17 More presentations in this session

Presentation thumbnail

Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients with atrial fibrillation on direct-acting oral anticoagulants

Mr A. Holt (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates

Mr A. Holt (Copenhagen, DK)

Abstract Slides

Presentation thumbnail

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

Mr Q. Ying (Ningbo, CN)

Abstract Slides

Presentation thumbnail

Antifibrotic and anti-inflammatory effects of the selective nonsteroidal MR antagonist finerenone in preclinical pulmonary fibrosis

Doctor M. Delbeck (Wuppertal, DE)

Abstract Slides

Presentation thumbnail

Aspirin vs. P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation: insights from the AFIRE trial

Assistant Professor H. Fukaya (Sagamihara, JP)

Abstract Slides

Access the full session

Session thumbnail

Congress committee e-posters choice in pharmacology and pharmacotherapy

The Event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

You may be interested in

Congress Presentation

Case 1 - a middle-aged male with T2DM: polypharmacy in a primary prevention setting

Congress Presentation

Hypertension and glucose

Congress Presentation

Cardiovascular risk reduction: should we target pre-diabetes?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources